MedTrace Logo

Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia

NCT02914977 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-01-14

No results posted yet for this study

Summary

In this pilot study, eligible patients will be treated with 5 days of low dose daunorubicin for one cycle only. Any patient who receives treatment on this protocol will be evaluable for toxicity. Each patient will be assessed for the development of toxicity at all scheduled visits (Days 1-5). Following participation on this brief pharmacodynamic trial, patients can then proceed to other conventional or investigational therapies, as clinically indicated.

Conditions

Interventions

DRUG

Daunorubicin

* Agent: Daunorubicin * Dose: 6.75 mg/m2/day * Route: IV * Schedule: Days 1-5 * Duration: One cycle

Sponsors & Collaborators

  • Tara Lin

    lead OTHER

Principal Investigators

  • Tara Lin, MD · University of Kansas Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-04-03
Completion
2021-07-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02914977 on ClinicalTrials.gov